What IKDC and MOCART scores actually measure

If you have been quoted an IKDC score or a MOCART rating after a cartilage consultation, two quite different things are being measured — and understanding each one makes the clinical evidence far easier to interpret.

IKDC Subjective Knee Score

The IKDC (International Knee Documentation Committee) Subjective Knee Score is an 18-item questionnaire completed by the patient, not the surgeon. Seven items cover symptoms such as pain and swelling, nine cover daily activities such as climbing stairs and squatting, and one addresses sports participation. Answers are combined into a single figure on a 0–100 scale, where 100 represents the highest level of knee function those 18 items can capture.

That ceiling matters: a score of 100 does not mean a 'perfect' knee — it means the patient reports no limitation across all 18 areas. In practice, scores around 80 are consistent with comfortable recreational activity and the absence of significant daily restriction. The other number worth knowing is the minimal clinically important difference (MCID): 16.7 points. Changes smaller than that are unlikely to be felt in day-to-day life; changes above it represent a genuine, noticeable improvement.

MOCART MRI Score

MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue), defined by Marlovits et al., is a radiologist's tool applied to post-procedure MRI scans. Scored on the same 0–100 range, it evaluates how well the repair tissue has filled the original defect, how it integrates with the surrounding native cartilage, whether the surface is congruent, and what signal the tissue produces — a proxy for tissue quality. A MOCART score above 80 indicates greater than 80% defect fill with good peripheral integration; it is best understood as a maturation indicator that evolves over months rather than a simple pass or fail.

Together, the two tools offer complementary perspectives: IKDC captures the patient's lived experience, MOCART provides structural confirmation on imaging. Neither is sufficient alone.

What ChondroFiller's IKDC results show

For a patient who starts treatment struggling with stairs and moderate-length walks, moving to comfortable recreational activity — cycling, swimming, a round of golf — is the kind of shift that changes how people manage daily life. That is approximately what a 30-point rise on the IKDC scale represents, and it is what four distinct clinical studies of ChondroFiller in focal knee cartilage defects consistently recorded.

The clearest dataset comes from the Jerosch et al. prospective post-market clinical follow-up (PMCF) study, which tracked patients over three years. The mean IKDC improvement was 32.4 points — nearly double the 16.7-point MCID threshold — and, crucially, those gains did not fade: scores were sustained, and marginally higher, at the three-year mark. The mean absolute score reached approximately 80 out of 100, the range routinely associated with comfortable participation in low-impact recreational activity rather than simply managing everyday tasks without restriction.

The consistency across all four studies carries independent weight. These are prospective observational investigations rather than randomised controlled trials, and the majority of the evidence originates from manufacturer-sponsored programmes — limitations worth stating plainly. But when four separate cohorts, assessed independently, each produce IKDC improvements that clear the same clinically meaningful threshold, the pattern becomes harder to attribute to noise in a single dataset. It suggests a reproducible functional benefit rather than a favourable outlier.

The practical implication for patients with eligible focal cartilage defects: the published evidence points to a level of functional recovery that goes meaningfully beyond symptom management alone.

What MOCART MRI scores reveal about the repair tissue

The 4-week MRI after a collagen scaffold injection is not a verdict. In one key ChondroFiller study, the mean MOCART score at that early stage was 65.3 — the scaffold still in active resorption, repair tissue only partially deposited. By 12 months, the same cohort's mean had risen to 81.6, and European ChondroFiller studies overall record final scores of 81.6 to 84.3. This progression reflects the underlying biology: the collagen matrix breaks down gradually as the patient's own progenitor cells lay down new tissue, and that process takes the better part of a year.

Scores in the 81–84 range carry specific clinical weight. The repair tissue has filled the defect, integrated at its margins with the surrounding native cartilage, and produces an MRI signal approaching that of normal cartilage — what surgeons look for as evidence of durable structural repair rather than superficial coverage. The literature describes this as 'hyaline-like', which is an imaging characterisation rather than a biopsy finding: MOCART measures morphological appearance, not tissue composition under a microscope.

For a patient awaiting a three-month scan, the practical implication is clear: incomplete fill at that stage is expected, not a warning sign. Repair tissue continues maturing well beyond that point, and the structural picture at 12 months — which aligns with the functional improvement pattern in the IKDC data — is the more meaningful clinical endpoint.

How ChondroFiller's results sit alongside other knee cartilage options

Placing ChondroFiller alongside other cartilage options is useful for perspective — provided the comparison is read carefully. These figures come from separate clinical literatures; no published randomised controlled trial has yet compared ChondroFiller head-to-head with microfracture or ACI/MACI in a single study, so direct statistical ranking is not possible.

That said, the functional outcomes reported across each option are informative. ChondroFiller's consistent ~30-point IKDC gain sits within the same range as ACI and MACI, which produce improvements of approximately 30–35 points in published series. The material difference lies in the procedure itself: ACI and MACI are two-stage surgical procedures carried out under anaesthesia in an operating theatre, with complication rates reported up to 17% and reoperation rates up to 37%. ChondroFiller, by contrast, is delivered as an outpatient injectable collagen scaffold — a single session under ultrasound guidance — with a reported complication rate of approximately 0% and a reoperation rate of 3–8%.

Microfracture is simpler and widely used as an alternative surgical pathway, but its results are more variable: reoperation rates of up to 41% have been reported in the literature, and it is generally suited to defects under 2–4 cm². ChondroFiller is indicated for focal defects up to 6 cm², which broadens the eligible patient group.

For patients weighing these routes, the relevant questions are defect size, stage of disease, and how the procedural demands of each pathway fit their circumstances — all of which a consultant assessment can address properly.

Gaps and limitations in the evidence

The evidence base carries two limitations worth naming plainly. The four knee studies sit within the manufacturer's post-market clinical follow-up (PMCF) framework rather than an independent randomised trial programme — and no published RCT has yet compared ChondroFiller directly against microfracture or ACI in a head-to-head design. The longest follow-up in any study is three years; whether the IKDC gains and MOCART scores hold beyond that window is not yet known.

Neither point dissolves the clinical signal. CE marking as a Class III medical device requires demonstration of safety and clinical performance — a different regulatory pathway from pharmaceutical drug approval, which mandates RCT evidence before market entry. Manufacturer-sponsored prospective registries are the standard evidentiary route in medical device evaluation, not a disqualifying weakness.

More practically: four separate prospective investigations, enrolling patients across different European centres, all return IKDC improvements of approximately 30 points — each independently exceeding the 16.7-point minimal clinically important difference. A systematic artefact that produces the same clinically meaningful number across independent cohorts would be unusual. The consistency of that pattern is itself informative, even in the absence of a randomised comparator.

For individual patients, these uncertainties reinforce the case for a thorough consultant assessment before proceeding — one that weighs defect size, symptom duration, and the full treatment picture rather than any single data point.

What the evidence means when you are weighing up treatment

Taken together, the evidence points most clearly to one patient profile: a confirmed focal defect — typically up to 6 cm² in a mechanically stable knee — where the priority is a single-session, outpatient approach rather than a staged surgical pathway. For that profile, a consistent 30-point IKDC improvement sustained across four prospective cohorts, and MOCART scores above 80 at twelve months, represent a genuinely encouraging signal rather than an isolated or manufacturer-inflated finding.

Two questions are worth raising in any consultation before this route is considered. First, how large and deep is the defect? Second, how healthy is the surrounding cartilage and subchondral bone? Both require proper imaging review. A MOCART above 80 signals good structural integration — but a scan taken at four or eight weeks will underread what the scaffold is doing; the meaningful picture emerges closer to one year. A defect that is too extensive, or a knee with widespread cartilage loss beyond the focal area, is unlikely to respond in the same way as the study populations described in the literature.

The scaffold pathway is not a guaranteed outcome for every patient who might want it. What the evidence does establish is a consistent, clinically meaningful improvement in a well-defined group — and a consultant assessment that maps defect size, depth, and adjacent tissue on MRI is the necessary first step in establishing whether a patient falls within that group.

Book a knee assessment

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without a GP referral. Assessments are available at Sleaford NG34 and Grantham NG31. Book at lincolnshireknee.co.uk.

1. [1] Articular cartilage repair — Wikipedia. https://en.wikipedia.org/?curid=19042351 https://en.wikipedia.org/?curid=19042351